eGenesis raised $191 million in a Series D financing led by Lux Capital to advance its lead program for kidney transplant.
eGenesis raised $191 million in a Series D financing led by Lux Capital to advance its lead program for kidney transplant.
09/04/24, 3:16 PM
Location
cambridgeMoney raised
$191 million
Industry
biotechnology
Investors
Parkwood Corporation, Natco Pharmaceuticals, Eisai Innovation, Da Vita, Leaps By Bayer, Fresenius Medical Care Ventures, Alta Partners, Farallon Capital Management, Khosla Ventures, Arch Ventures, Lux Capital
eGenesis, a biotechnology company, announced the close of a $191 million Series D financing to further its lead product candidate, EGEN-2784, into first-in-human studies. The funding will also help advance additional pipeline programs and scale production.
Company Info
Location
300 technology square
cambridge, massachusetts, united states
Additional Info
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.